Financial Data and Key Metrics Changes - Omada Health achieved a 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][29] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - The company achieved its first quarter of positive GAAP net income in Q4, reporting $5 million, and delivered positive full-year adjusted EBITDA of $6 million [4][34] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][69] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, and members on average achieved greater weight loss compared to published real-world evidence [10][11] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million estimated eligible lives [18] - The company noted strong performance across multiple channels, including a successful launch of a large new channel partner [17] Company Strategy and Development Direction - Omada Health is focused on expanding its multi-condition platform, which includes weight health, diabetes, hypertension, and cholesterol management, to provide integrated care solutions [8][24] - The company aims to leverage AI to enhance member support and operational efficiency, embedding AI throughout its services [12][66] - The strategy includes maintaining a balance between growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with momentum and a clear plan, highlighting the strong market demand for chronic care solutions and AI-driven innovation [4][5] - The company anticipates 2026 revenue in the range of $312 million to $322 million, reflecting a 22% growth over 2025 [36][37] Other Important Information - Omada Health's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, and adjusted gross margin reached an all-time high of 73% [30][31] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [36] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions and does not include new opportunities like GLP-1 prescribing or FlexCare, which could provide upside [42][46] Question: How did January and February track in terms of conversions? - Management reported strong performance in closing additional eligible covered lives and improved enrollment rates, indicating positive trends early in 2026 [48] Question: What is the impact of the new GLP-1 FlexCare program on economics? - The FlexCare program allows employers to support employees with structured models for GLP-1 access, which includes compensation for Omada for facilitating connections [53][56] Question: How is Omada leveraging AI to improve operations? - Omada is utilizing AI for member support and operational efficiencies, with a focus on unique data sets that enhance personalized care [65][66] Question: What traction is being seen in hypertension and diabetes programs? - Management noted strong growth in both diabetes and hypertension programs, reflecting the integrated cardiometabolic care approach [68][69]